Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference
Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cystic fibrosis (CF), has announced its participation in the 45th Annual TD Cowen Health Care Conference. The company's management will deliver a presentation on Monday, March 3, 2025, at 3:10 p.m. ET.
The presentation will be accessible through a live webcast on the company's investor relations website in the 'Events' section at investors.sionnatx.com. Interested parties who cannot attend the live presentation will have access to a replay, which will remain available for 90 days following the event.
Sionna's mission centers on revolutionizing CF treatment by developing new medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Sionna Therapeutics (Nasdaq: SION), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di trattamenti innovativi per la fibrosi cistica (FC), ha annunciato la sua partecipazione alla 45ª Conferenza Annuale TD Cowen sulla Salute. La direzione dell'azienda presenterà un intervento Lunedì 3 Marzo 2025, alle 15:10 ET.
La presentazione sarà accessibile tramite un webcast dal vivo sul sito web delle relazioni con gli investitori dell'azienda, nella sezione 'Eventi' su investors.sionnatx.com. Le parti interessate che non possono partecipare alla presentazione dal vivo avranno accesso a una registrazione, che rimarrà disponibile per 90 giorni dopo l'evento.
La missione di Sionna è incentrata sulla rivoluzione del trattamento della FC sviluppando nuovi farmaci che normalizzino la funzione del regolatore della conduttanza transmembrana della fibrosi cistica (CFTR).
Sionna Therapeutics (Nasdaq: SION), una empresa biofarmacéutica en etapa clínica centrada en desarrollar tratamientos innovadores para la fibrosis quística (FQ), ha anunciado su participación en la 45ª Conferencia Anual de Atención Médica de TD Cowen. La dirección de la empresa realizará una presentación el Lunes 3 de Marzo de 2025, a las 3:10 p.m. ET.
La presentación será accesible a través de un webcast en vivo en el sitio web de relaciones con inversores de la empresa, en la sección 'Eventos' en investors.sionnatx.com. Las partes interesadas que no puedan asistir a la presentación en vivo tendrán acceso a una repetición, que estará disponible durante 90 días después del evento.
La misión de Sionna se centra en revolucionar el tratamiento de la FQ desarrollando nuevos medicamentos que normalicen la función del regulador de la conductancia transmembrana de fibrosis quística (CFTR).
Sionna Therapeutics (Nasdaq: SION), 혁신적인 낭포성 섬유증 (CF) 치료제를 개발하는 데 집중하는 임상 단계의 생명공학 회사가 제45회 TD Cowen 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2025년 3월 3일 월요일, 오후 3시 10분 ET에 발표를 진행할 예정입니다.
발표는 회사의 투자자 관계 웹사이트 '이벤트' 섹션에서 실시간 웹캐스트를 통해 접근할 수 있습니다. 생중계 발표에 참석할 수 없는 관심 있는 분들은 이벤트 후 90일 동안 이용할 수 있는 재생에 접속할 수 있습니다.
Sionna의 사명은 낭포성 섬유증 세포막 전도 조절 단백질 (CFTR)의 기능을 정상화하는 새로운 약물을 개발하여 CF 치료를 혁신하는 데 중점을 두고 있습니다.
Sionna Therapeutics (Nasdaq: SION), une entreprise biopharmaceutique en phase clinique axée sur le développement de traitements innovants pour la fibrose kystique (FK), a annoncé sa participation à la 45ème Conférence Annuelle TD Cowen sur les Soins de Santé. La direction de l'entreprise fera une présentation le Lundi 3 Mars 2025, à 15h10 ET.
La présentation sera accessible via un webinaire en direct sur le site web des relations investisseurs de l'entreprise, dans la section 'Événements' à investors.sionnatx.com. Les parties intéressées qui ne peuvent pas assister à la présentation en direct auront accès à un enregistrement, qui restera disponible pendant 90 jours après l'événement.
La mission de Sionna est de révolutionner le traitement de la FK en développant de nouveaux médicaments qui normalisent la fonction du régulateur de la conductance transmembranaire de la fibrose kystique (CFTR).
Sionna Therapeutics (Nasdaq: SION), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer Behandlungen für zystische Fibrose (CF) konzentriert, hat seine Teilnahme an der 45. jährlichen TD Cowen Gesundheitskonferenz angekündigt. Die Unternehmensleitung wird am Montag, den 3. März 2025, um 15:10 Uhr ET eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens im Bereich 'Veranstaltungen' unter investors.sionnatx.com zugänglich sein. Interessierte, die nicht an der Live-Präsentation teilnehmen können, haben Zugang zu einer Aufzeichnung, die 90 Tage nach der Veranstaltung verfügbar bleibt.
Die Mission von Sionna konzentriert sich darauf, die Behandlung von CF zu revolutionieren, indem neue Medikamente entwickelt werden, die die Funktion des Regulators der zystischen Fibrose-Transmembranleitfähigkeit (CFTR)-Protein normalisieren.
- None.
- None.
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the 45th Annual TD Cowen Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET.
A live webcast of the presentation will be available the day of the event on the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. A replay will be available for 90 days following the event.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for CF by developing novel medicines that normalize the function of the CFTR protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (NBD1), which the company believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, the company is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact
Adam Daley
CG Life
212.253.8881
adaley@cglife.com
Investor Contact
Juliet Labadorf
ir@sionnatx.com
FAQ
When is Sionna Therapeutics (SION) presenting at the TD Cowen Health Care Conference 2025?
How long will the replay of Sionna's (SION) TD Cowen conference presentation be available?
Where can investors watch Sionna Therapeutics' (SION) TD Cowen conference presentation?
What is Sionna Therapeutics' (SION) main focus in cystic fibrosis treatment?
